全文获取类型
收费全文 | 604篇 |
免费 | 56篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 19篇 |
妇产科学 | 6篇 |
基础医学 | 63篇 |
口腔科学 | 44篇 |
临床医学 | 57篇 |
内科学 | 123篇 |
皮肤病学 | 21篇 |
神经病学 | 10篇 |
特种医学 | 96篇 |
外科学 | 93篇 |
综合类 | 27篇 |
预防医学 | 27篇 |
眼科学 | 7篇 |
药学 | 44篇 |
中国医学 | 1篇 |
肿瘤学 | 36篇 |
出版年
2023年 | 5篇 |
2022年 | 4篇 |
2021年 | 6篇 |
2020年 | 6篇 |
2018年 | 19篇 |
2017年 | 8篇 |
2016年 | 14篇 |
2015年 | 10篇 |
2014年 | 10篇 |
2013年 | 13篇 |
2012年 | 17篇 |
2011年 | 26篇 |
2010年 | 21篇 |
2009年 | 30篇 |
2008年 | 13篇 |
2007年 | 34篇 |
2006年 | 8篇 |
2005年 | 15篇 |
2004年 | 13篇 |
2003年 | 12篇 |
2002年 | 15篇 |
2001年 | 10篇 |
2000年 | 12篇 |
1999年 | 11篇 |
1998年 | 23篇 |
1997年 | 38篇 |
1996年 | 35篇 |
1995年 | 19篇 |
1994年 | 17篇 |
1993年 | 19篇 |
1992年 | 5篇 |
1991年 | 9篇 |
1989年 | 17篇 |
1988年 | 19篇 |
1987年 | 11篇 |
1986年 | 13篇 |
1985年 | 17篇 |
1984年 | 11篇 |
1983年 | 13篇 |
1982年 | 8篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 3篇 |
1973年 | 3篇 |
1972年 | 3篇 |
1969年 | 3篇 |
1967年 | 4篇 |
排序方式: 共有677条查询结果,搜索用时 15 毫秒
101.
102.
Krösser S Tillner J Fluck M Ungethüm W Wolna P Kovar A 《International journal of clinical pharmacology and therapeutics》2007,45(5):271-280
OBJECTIVE: Sarizotan is a 5-HTIA receptor agonist with high affinity for D3 and D4 receptors. Here we report the pharmacokinetic and tolerability results from four Phase 1 studies. MATERIALS: Two single-dose (5 -25 mg, n = 25, 0.5 - 5 mg, n = 16) and two multiple-dose (10 and 20 mg b.i.d., n = 30, 5 mg b.i.d., n = 12) studies with orally administered sarizotan HCl were carried out in healthy subjects. METHODS: Plasma sarizotan HCl concentrations were measured using a validated HPLC method and fluorescence or MS/MS detection. Pharmacokinetic parameters were obtained using standard non-compartmental methods. RESULTS: Sarizotan was rapidly absorbed, group-median times to reach maximum concentration (tmax) ranged from 0.5 -2.25 h after single doses and during steady state. Maximum plasma concentration (Cmax) and tmax were slightly dependent on formulation and food intake, whereas area under the curve (AUC) was unaffected by these factors. AUC and Cmax increased dose-proportionally over the tested dose range. Independently of dose and time, sarizotan HCl plasma concentrations declined polyexponentially with a terminal elimination half-life (t1/2) of 5 - 7 h. Accumulation factors corresponded to t1/2 values, and steady state was reached within 24 h. Plasma metabolite concentrations were considerably lower than those of the parent drug. The ratio metabolite AUC : parent drug AUC was time- and dose-independent for all three metabolites suggesting that the metabolism of sarizotan is non-saturable in the tested dose range. CONCLUSIONS: The pharmacokinetics of sarizotan were dose-proportional and time-independent for the dose range 0.5 -25 mg). The drug was well-tolerated by healthy subjects up to a single dose of 20 mg. 相似文献
103.
In earlier studies we have shown that a final concentration of 0.69% glycerol in blood mixed with an experimental additive solution, EAS 25, improves the in vitro quality and in vivo survival of red blood cells (RBCs). The objective of this study was to determine if the better preservation of RBCs in EAS 25 is correlated with the improved maintenance of membrane lipids and proteins and decreased vesiculation. Split units of RBCs were stored in Adsol or EAS 25 (mmol/L: adenine 2/2, dextrose 122/110, mannitol 42/55, glycerol 0/150, NaCl 154/50). After 12 weeks storage, RBC and microvesicle membranes were analyzed for cholesterol, phospholipid, diphenyl hexatriene fluorescence anisotropy, and acetylcholinesterase (AchE) activity. Bands 3 and 4.1 were identified in the microvesicle membranes by immunoblotting. The RBC membrane cholesterol, phospholipids, and AchE remained higher in EAS 25 than in Adsol (P < .001). Vesicle membrane lipids and AchE in EAS 25 were significantly less than in Adsol (P < .001). The fluidity of stored cells in both the solutions was greater than the prestorage samples. Immunoblotting analyses showed that bands 3 and 4.1 were greatly reduced in the microvesicle membranes shed by the RBCs stored in EAS 25 compared with those formed in Adsol. 相似文献
104.
To clarify the defective erythropoiesis in eight patients with Diamond- Blackfan anemia, we studied their bone marrow response in vitro to recombinant human interleukin-3 (IL-3) and recombinant granulocyte- macrophage colony-stimulating factor (GM-CSF). In an erythropoietin- containing assay system, specimens from six of the eight patients yielded low numbers of erythroid colonies compared to control values, and in five of these no erythropoietin dose-response could be elicited. Addition of IL-3, GM-CSF or both to cultures from the six patients had no effect on CFU-E-derived colonies. In contrast, IL-3 but not GM-CSF induced a marked increase in the number (183%) and size of the BFU-E- derived colonies in five of the six cases and partially corrected the impaired dose-response to erythropoietin in four. Bone marrow from the other two patients yielded numbers of CFU-E and BFU-E colonies comparable to controls and manifested similar increments in colonies with increasing concentrations of erythropoietin. When IL-3 was added to these cultures, further increments were observed in the number and size of BFU-E colonies. We conclude that IL-3 enhanced the marrow erythropoiesis in most of the patients and exerted a corrective effect on the aberrant colony formation in the presence of erythropoietin. The data raise the possibility of IL-3 as a therapeutic agent in Diamond- Blackfan anemia. 相似文献
105.
We have previously reported the isolation of a monoclonal antibody (NHL- 30.5) that reacts with an antigen expressed on a substantial proportion of marrow and blood cells of most patients with newly diagnosed or relapsing acute myeloid leukemia. This antigen is also found on several cell lines derived from myeloid malignancies of human origin. It is not present on mature hemopoietic cells or on the majority of differentiating bone marrow cells. In order to determine whether the NHL-30.5 antigen may, nevertheless, be expressed on low-frequency primitive normal hemopoietic cells, not detected in standard antibody screening procedures, its expression was studied on clonogenic erythropoietic and granulopoietic cells. Light-density (less than 1.077 g/mL) suspensions of normal or chronic myelogenous leukemia bone marrow and peripheral blood cells were stained with NHL-30.5 and fluorescein isothiocyanate labeled second antibody and then sorted into two fractions using the fluorescence-activated cell sorter. The first contained the top 5% of cells with the highest fluorescence intensity. The remainder were collected in the second fraction. Colony assays of both fractions showed the first to be enriched in CFU-E, BFU-E, and CFU- C content (fourfold to 17-fold). The second fraction was correspondingly depleted of these progenitors. These findings reveal NHL-30.5 antigen expression to be a transient event during normal hemopoiesis that characterizes primitive hemopoietic cells on several pathways. Subsequent experiments showed that the presence of up to 10 micrograms/mL of purified NHL-30.5 antibody in colony assay cultures neither inhibited nor stimulated colony formation. Marrow fibroblasts (subcultured marrow adherent cells) were NHL-30.5 negative. Immunoprecipitation studies showed that the antigen detected by NHL- 30.5 is clearly distinct from that identified by My-10, another monoclonal antibody that has previously shown some similarities to NHL- 30.5. It thus appears that the NHL-30.5 antibody reacts with a new myeloid differentiation antigen of as yet unidentified function that is normally restricted in its expression to early stages of hemopoiesis. 相似文献
106.
107.
Background: A case control study was carried out to study the emerging risk factors for coronary artery disease in Indians. 相似文献
108.
109.
S Fluck W McKane T Cairns V Fairchild A Lawrence J Lee D Murray M Polpitiye A Palmer D Taube 《Nephrology, dialysis, transplantation》1999,14(7):1687-1691
BACKGROUND: In December 1996 we identified an outbreak of erythropoietin (rHuEpo) resistance requiring a substantial increase in rHuEpo dosage in one of our four haemodialysis (HD) units. The dialysate chloramine levels in this unit had risen from <0.1 p.p.m. in 1996 to 0.25-0.3 p.p.m. in 1997. In the other three HD units levels remained <0.1 p.p.m. Other parameters of water quality were within accepted standards. METHODS: Monthly records of haemoglobin level and rHuEpo dose were available for 148 patients between January 1996 and May 1998. Seventy-two patients, with no recognized cause of rHuEpo resistance, were analysed in detail (August 1997 to April 1998). A subgroup of 15 patients was examined for evidence of haemolysis during HD (methaemoglobin and haptoglobin levels, reticulocyte counts and Heinz bodies). Larger carbon columns were installed in December 1997 to effect chloramine removal. RESULTS: There was an increase in mean methaemoglobinaemia of 23% (P<0.01) and a 21% fall in mean haptoglobin (P<0.01) across HD, although no patient had a reticulocytosis and only one patient with G6PD deficiency had Heinz bodies. Following installation of larger carbon columns there was an 18.6% rise (P<0.001) in mean haemoglobin level and a subsequent 25.0% reduction (P<0.001) in mean rHuEpo dose. Intradialytic changes in methaemoglobin and haptoglobin were abolished. The dialysate chloramine levels fell to < 0.1 p.p.m. Water company records subsequently revealed a sustained twofold increase in mains water chloramine from November 1996. CONCLUSIONS: This is the first report linking chloramine exposure and rHuEpo resistance, with only subtle signs of haemolysis. Unheralded changes in mains water constituents can directly affect dialysate water quality and clinical outcomes. 相似文献
110.
目的:确定塞来昔布对于经常服用稳定剂量甲氨喋呤(MTX)治疗类风湿性关节炎(RA)患者的肾脏清除率和血浆药代动力学方面的影响。方法:选取14例至少已服用MTX3个月,且每个星期的剂量稳定在5-15mg,有类风湿关节炎的成年妇女,随机给予塞来昔布(200mg.bid)或安慰剂单盲治疗,每一阶段7,分二阶段交叉试验,研究MTX的药代动力学和肾脏平均清除率。结果:当MTX和塞来昔布或安慰剂合用时,MTX 相似文献